Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

Overview of attention for article published in Cardiovascular Diabetology, September 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (70th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 10,565 followers.

RT @drleonjimenez: Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type…

RT @drleonjimenez: Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type…

RT @drleonjimenez: Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type…

RT @drleonjimenez: Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.